Pyxis Oncology (PYXS) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Pyxis Oncology (PYXS) over the past year, gaining 75.5% versus a loss of 21.2%. Over five years, SLGL leads with a -22.8% price change compared with -82.9% for PYXS. Pyxis Oncology is the larger company by market cap ($238.3 million vs $228.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PYXS | SLGL |
|---|---|---|
| Share price | $2.00 | $69.65 |
| Market cap | $238.31M | $228.03M |
| 1-day change | -0.75% | -3.19% |
| YTD return | +74.78% | +70.73% |
| 1-year return | -21.18% | +75.52% |
| 5-year return | -82.92% | -22.85% |
| EPS (TTM) | $-1.40 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.55 | $97.97 |
| 52-week low | $1.03 | $28.81 |
| Distance from 52-week high | -64.05% | -28.91% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +334.59% | +118.95% |
| Average volume | 1.25M | 55.30K |
| Shares outstanding | 119.46M | 3.27M |
| Employees | 56 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed PYXS by 96.7 percentage points over the past year.
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
PYXS vs SLGL FAQ
Which is bigger, Pyxis Oncology or Sol-Gel Technologies?
Pyxis Oncology (PYXS) is larger, with a market capitalization of $238.31M compared with $228.03M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, PYXS or SLGL?
SLGL returned +75.52% over the past 12 months, compared with -21.18% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are Pyxis Oncology and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.